On Tuesday, Ball Corporation (NYSE:BLL)’s shares inclined 0.18% to $70.63.
Ball Aerospace & Technologies Corp. salutes NASA, the John Hopkins Applied Physics Laboratory and the Southwest Research Institute (SwRI) for bringing us never-before-seen images of the dwarf planet Pluto from the New Horizons mission. Ball’s Ralph instrument is the “eyes” of the new Horizons mission and has travelled for nearly a decade through the extreme cold and radiation of space to map Pluto and its moons.
After traveling nearly ten years and three billion miles, New Horizons passed by Pluto on July 14, 2015 coming within 7,000 miles of Pluto’s icy surface before shooting into the unexplored region known as the Kuiper Belt.
Ball Corporation, together with its auxiliaries, supplies metal packaging products to the beverage, food, personal care, and household products industries worldwide. It operates in four segments: Metal Beverage Packaging, Americas and Asia; Metal Beverage Packaging, Europe; Metal Food and Household Products Packaging; and Aerospace and Technologies. The Metal Beverage Packaging, Americas and Asia segment manufactures and sells metal beverage containers for use in beverage packaging. The Metal Beverage Packaging, Europe segment manufactures and sells metal beverage containers in Europe.
Baytex Energy Corp (USA) (NYSE:BTE)’s shares dropped -0.80% to $13.70.
Baytex Energy Corp. (BTE) reports that a cash dividend of $0.10 per common share in respect of July operations will be paid on August 14, 2015 to shareholders of record on July 23, 2015. The ex-dividend date is July 21, 2015. This dividend is an eligible dividend for the purposes of the Income Tax Act (Canada).
The U.S. dollar equivalent dividend amount is about US$0.0787 per share assuming a foreign exchange rate of $0.7865 USD/CAD. The actual U.S. dollar equivalent dividend for shareholders who hold through a brokerage firm will be based on the exchange rate in effect on the payment date and net of applicable Canadian withholding taxes. Registered shareholders are paid directly by Baytex’s transfer agent, Valiant Trust Company, and the actual U.S. dollar equivalent dividend will be based on the exchange rate in effect on the record date and paid net of applicable Canadian withholding taxes.
Baytex Energy Corp., an oil and gas company, engages in the acquisition, development, exploitation, and production of oil and natural gas in the Western Canadian Sedimentary Basin and the United States. The company offers heavy oil, light oil, condensate, and natural gas liquids.
At the end of Tuesday’s trade, c)‘s shares dipped -1.78% to $62.97.
Triumph Group, Inc. (TGI) will release first quarter fiscal year 2016 earnings on July 29, 2015. Richard C. Ill, Triumph’s President and Chief Executive Officer, and Jeffrey L. McRae, Triumph’s Senior Vice President and Chief Financial Officer, will host a conference call that day at 8:30 a.m. ET. A slide presentation will be comprised of with the audio portion of the webcast.
Triumph Group, Inc. designs, engineers, manufactures, repairs, overhauls, and distributes aero structures, aircraft components, accessories, subassemblies, and systems worldwide. Its Aerostructures Group segment designs, manufactures, builds, and repairs acoustic and thermal insulation systems, aircraft wings, composite and metal bonding, composite ducts and floor panels, empennages, engine nacelles, flight control surfaces, helicopter cabins, precision machined parts, stretch-formed leading edges and fuselage skins, and wing spars and stringers.
Mallinckrodt PLC (NYSE:MNK), ended its Tuesday’s trading session with 2.03% gain, and closed at $124.04.
Mallinckrodt plc (MNK) will report third quarter fiscal 2015 results on Tuesday, August 4, 2015. A conference call for investors will start at 8:30 a.m. U.S. Eastern time.
Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, counting neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the administration of spasticity of cerebral or spinal origin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
